| Lymphoma, Follicular
Brukinsa vs Tazverik
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Brukinsa vs Tazverik with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazverik has a higher rate of injection site reactions vs Brukinsa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazverik but not Brukinsa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brukinsa
Tazverik
At A Glance
Oral
Once or twice daily
BTK inhibitor
Oral
Twice daily
EZH2 methyltransferase inhibitor
Indications
- Mantle cell lymphoma
- Waldenstrom Macroglobulinemia
- Marginal Zone B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
- Sarcoma, Epithelioid
- Lymphoma, Follicular
Dosing
Mantle cell lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 160 mg orally twice daily or 320 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular 160 mg orally twice daily in combination with obinutuzumab, with or without food, until disease progression or unacceptable toxicity.
Sarcoma, Epithelioid 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity.
Lymphoma, Follicular 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity; select patients based on EZH2 mutation of codons Y646, A682, or A692 for EZH2-mutant R/R FL.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Neutrophil count decreased, platelet count decreased, upper respiratory tract infection, hemorrhage, musculoskeletal pain
Serious Hemorrhage, pneumonia, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury
Postmarketing Drug-induced liver injury
Most common (>=20%) - Sarcoma, Epithelioid pain, fatigue, nausea, decreased appetite, vomiting, constipation
Most common (>=20%) - Lymphoma, Follicular fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, abdominal pain
Serious - Sarcoma, Epithelioid hemorrhage, pleural effusion, skin infection, dyspnea, pain, respiratory distress
Serious - Lymphoma, Follicular general physical health deterioration, abdominal pain, pneumonia, sepsis, anemia
Pharmacology
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity and thereby blocking B-cell proliferation, trafficking, chemotaxis, and adhesion pathways driven by B-cell antigen receptor and cytokine receptor signaling.
Tazemetostat is a selective inhibitor of EZH2 methyltransferase and certain gain-of-function mutations (Y646X, A682G, A692V), blocking trimethylation of histone H3 lysine 27 and relieving transcriptional repression that drives tumor growth in epithelioid sarcoma (via SWI/SNF complex dysfunction) and B-cell lymphoma with or without EZH2 mutation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brukinsa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Tazverik
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (3/12)
UnitedHealthcare
Brukinsa
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (4/8)
Tazverik
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Brukinsa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Tazverik
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brukinsa.
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrukinsaView full Brukinsa profile
TazverikView full Tazverik profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.